BTK and COVID-19: Based on this rationale, the covalent inhibitor of BTK acalbrutinib has been used in a small open-label trial of 19 patients with severe COVID-19 demonstrating some degree of clinical success as well as ex vivo evidence of elevated BTK activity [57].